NCT02365532View on ClinicalTrials.gov

Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Long QT Syndrome
Interventions
DRUG

GS-6615

GS-6615 tablets administered orally

DRUG

Placebo to match GS-6615

Placebo to match GS-6615 tablets administered orally

DRUG

Placebo to match dofetilide

Placebo to match dofetilide capsules administered orally

DRUG

Dofetilide

Dofetilide 500 μg capsules administered orally according to the current prescribing information

Trial Locations (1)

53095

Spaulding Clinical Research, LLC, West Bend

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY